The use of zoledronic acid in pediatric cancer patients. - Wikidata - wikimedia - TriplyDB

The use of zoledronic acid in pediatric cancer patients.

The use of zoledronic acid in pediatric cancer patients.

http://www.wikidata.org/entity/Q37836669

about

Bisphosphonate therapy in pediatric patients Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child.Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Pediatric Oncology: Managing Pain at the End of Life.Zoledronic acid in pediatric metabolic bone disorders.Effects of Pamidronate on Dental Enamel Formation Assessed by Light Microscopy, Energy-Dispersive X-Ray Analysis, Scanning Electron Microscopy, and Microhardness Testing.

P2860

Q26830702-6F657377-6378-4932-9389-0AA8AEEC37F0 Q33430116-340153B5-608C-47EF-956E-920C99840902 Q36433566-D08C1624-8048-4C45-AB87-50B38106C579 Q36946864-E5E8A5E5-232F-447F-BB25-14A313E0B520 Q38764080-17E4CE76-892C-4B84-AFCB-EBAEFFC2A91F Q47139370-B4E1437E-23F9-4A71-AD9C-709902A57F84 Q53096539-E0E00992-FD38-46BD-A454-4F10EC7E22A7

P2860

The use of zoledronic acid in pediatric cancer patients.

http://www.wikidata.org/entity/Q37836669

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 December 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The use of zoledronic acid in pediatric cancer patients.

@en

The use of zoledronic acid in pediatric cancer patients.

@nl

type

label

The use of zoledronic acid in pediatric cancer patients.

@en

The use of zoledronic acid in pediatric cancer patients.

@nl

prefLabel

The use of zoledronic acid in pediatric cancer patients.

@en

The use of zoledronic acid in pediatric cancer patients.

@nl

P1433

Q37836669-4EAFB0C1-0465-4139-8688-8B47ADBF531B

P1476

Q37836669-595565EF-AAAF-4B7F-9F06-61684246B8E3

P2093

Q37836669-43D62863-C812-40AF-8281-D974A6ABC1B4

Q37836669-518565D9-2955-431E-9182-298C1AB49767

Q37836669-5B304A75-0534-4CDA-8BFF-986F1C04C1A6

Q37836669-880DB4FA-5B75-40BD-AB92-A92F9EFA9B07

Q37836669-8FBFA922-FD19-40E2-A9A6-A45428125D5F

Q37836669-90120D05-EF43-43FB-8D5D-5F95C162081E

Q37836669-D27C5381-68FD-4418-9CDE-3DDB45F6A40E

P2860

Q37836669-0F7C28A5-F979-4245-B572-9A34D28A74F0

Q37836669-0F93DCAA-EFAB-4CF8-B267-30E7BBB81ECB

Q37836669-1855121C-7DDA-4DBC-AFF4-7B28F6BD7D81

Q37836669-19382B56-241E-46DE-AED9-71770E231F32

Q37836669-1A088457-D9AC-4025-9163-33D19E406869

Q37836669-21FA7418-F14A-4464-A214-2E23B4A39B4B

Q37836669-4B7EA600-9A78-45B9-83AE-124985616CA1

Q37836669-5107B727-D46B-499F-888E-3D71DBFE22D9

Q37836669-5A35B990-0D3A-43D8-A3BA-246EDA4F44F2

Q37836669-709F05BC-0355-4F7C-9CE4-325AEBC9FEFA

P304

Q37836669-295440E1-0E37-406C-9DA8-CA183817FF93

P31

Q37836669-ADC5445E-AEC1-4D2A-8DD0-30168883BBC4

P356

Q37836669-D359F37A-CBDA-469B-9265-097B424F2DFC

P433

Q37836669-8D3B110A-EFBE-44B0-A6A0-39967B91AE5B

P478

Q37836669-F102874E-C39C-49DA-90C4-8ADD0573DB31

P577

Q37836669-9DD200FA-312D-4CA6-8CD4-24DE42D00B7F

P698

Q37836669-0737AC1B-93AF-41BF-922D-7339E0D8773B

P356

P1433

Pediatric Blood & Cancer

P1476

The use of zoledronic acid in pediatric cancer patients.

@en

P2093

Amanda Dalton

http://www.w3.org/2001/XMLSchema#string

Bradley George

http://www.w3.org/2001/XMLSchema#string

Howard M Katzenstein

http://www.w3.org/2001/XMLSchema#string

Karen Wasilewski-Masker

http://www.w3.org/2001/XMLSchema#string

Keith J August

http://www.w3.org/2001/XMLSchema#string

Louis B Rapkin

http://www.w3.org/2001/XMLSchema#string

Thomas A Olson

http://www.w3.org/2001/XMLSchema#string

P2860

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease.

Use of bisphosphonate therapy for osteoporosis in childhood and adolescence.

Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.

Recommendations for zoledronic acid treatment of patients with bone metastases.

Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.

Bisphosphonates for treatment and prevention of bone metastases.

P304

610-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22681

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21298747

http://www.w3.org/2001/XMLSchema#string